A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD

Geoffrey A. Block*, Martha S. Block, Gerard Smits, Rupal Mehta, Tamara Isakova, Myles Wolf, Glenn M. Chertow

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Background Researchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD–related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in this population. Methods To investigate whether fixed-dose ferric citrate coordination complex favorably affects multiple biochemical parameters in patients with advanced CKD, we randomly assigned 203 patients with eGFR≤20 ml/min per 1.73 m2 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months after starting dialysis. No single biochemical end point was designated as primary; sample size was determined empirically.Results The two groups had generally similar baseline characteristics, although diabetes and peripheral vascular disease were more common in the usual-care group. Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (P<0.001 for all). Of the 133 patients randomized to ferric citrate coordination complex, 31 (23%) initiated dialysis during the study period, as did 32 of 66 (48%) patients randomized to usual care (P=0.001). Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation (P=0.002).Conclusions The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory results regarding the composite end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent safety profile in an unselected population with advanced CKD and merits further study.

Original languageEnglish (US)
Pages (from-to)1495-1504
Number of pages10
JournalJournal of the American Society of Nephrology
Volume30
Issue number8
DOIs
StatePublished - Aug 2019

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD'. Together they form a unique fingerprint.

Cite this